Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential a ‘bank run’ in private credit?
stocks
Shares leap for ASX rare earths provider
We increased our fair value based on higher expected rare earths pricing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.40 | 29.00 | -0.33% |
| CAC 40 | 7,984.44 | 72.92 | -0.91% |
| DAX 40 | 23,589.65 | 50.38 | -0.21% |
| Dow JONES (US) | 46,677.85 | 739.42 | -1.56% |
| FTSE 100 | 10,305.15 | 48.62 | -0.47% |
| HKSE | 25,716.76 | 182.00 | -0.70% |
| NASDAQ | 22,311.98 | 404.16 | -1.78% |
| Nikkei 225 | 54,452.96 | 572.41 | -1.04% |
| NZX 50 Index | 13,113.75 | 85.54 | -0.65% |
| S&P 500 | 6,672.62 | 103.18 | -1.52% |
| S&P/ASX 200 | 8,629.00 | 14.20 | -0.16% |
| SSE Composite Index | 4,129.10 | 4.33 | -0.10% |